Select Page
IBEX logo compact grey green
swiss flag

Natural products and probiotics

IBEX Therapeutics, a Swiss company specialised in therapies based on biological products derived from plant extracts.
?

Indications & medical needs

Oral mucositis, an inflammation of the oral mucosa, is a common side effect of chemotherapy, occurring in 15 to 50% of patients. Depending on its severity, it leads to painful inflammation and ulcerations that can impact the course of disease treatment and patient’s quality of life.

  • Villa A et al. An update on pharmacotherapies in active development for the management of cancer regimen-associated oral mucositis. Expert Opinion Pharmacother 2020. Elad S et al. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy. Cancer 2020.

Indications & medical needs

The indications and medical needs are well defined, with no known barriers to diagnosis and treatment: patients receiving chemotherapy or radiotherapy known to be mucitogenic should receive preventive treatment for oral mucositis.

Annual number of patients

Undergoing oncology treatment suffering from oral mucositis / candidiasis: CH = 32,700; EU-5 = 772,000 patients.

Existing therapeutic solutions

Despite its frequency and impact, the therapeutic options for mucositis are still limited: sodium bicarbonate solution (most commonly used), triazoles, amphotericin B, KGF-1, Photobiomodulation, benzydamine. These available therapeutic options have questionable efficacy vs. cost and/or tolerability profiles and none is currently recognized as standard of care.

A

Oral mucositis: common side effect of cancer treatments

Oral mucositis is a common adverse effect of cytotoxic cancer treatments. It remains one of the most painful and disruptive adverse effects of chemotherapy and radiotherapy. Despite its frequency and impact, preventive or therapeutic options remain limited. These available therapeutic options have questionable efficacy vs. cost and/or tolerability profiles and none is currently recognized as standard of care.

  • (Upper image) Large ulceration of the lower labial mucosa of a patient receiving deforolimus (AP23573) is shown. The borders were irregular. Although the ulcer was not penetrating, it was extremely painful. The clinical appearance was identical to that of major aphthous stomatitis.
  • Oral candidiasis, 51-year-old female, after the 18th fraction of radiotherapy in the OPC group. Whitish pseudomembranes and drops (arrows) are observed on the hard palate, which is devoid of mucositis (A). (A). Mucositis grade 2 to 3, 57-year-old male, after the 25th fraction of radiotherapy in the non-OPC group. Whitish pseudomembranes and drops (arrows) are observed on the hard palate, which is devoid of mucositis (A). (B). (OPC: oropharyngeal candidiasis)
  • (Picture 1 – mouth) – Sonis S et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010
  • (Pictures 2 & 3 – esophagus) – Qiu WZ et al. A retrospective study of 606 cases of nasopharyngeal carcinoma with or without oropharyngeal candidiasis during radiotherapy. PLOS one 2017
A
A
A
Mucites buccale 1
  • (Upper image) Large ulceration of the lower labial mucosa of a patient receiving deforolimus (AP23573) is shown. The borders were irregular. Although the ulcer was not penetrating, it was extremely painful. The clinical appearance was identical to that of major aphthous stomatitis.
Mucite buccale 2
Mucite buccale 3

Oral mucositis: common side effect of cancer treatments

Oral mucositis is a common adverse effect of cytotoxic cancer treatments. It remains one of the most painful and disruptive adverse effects of chemotherapy and radiotherapy. Despite its frequency and impact, preventive or therapeutic options remain limited. These available therapeutic options have questionable efficacy vs. cost and/or tolerability profiles and none is currently recognized as standard of care.

Mucites buccale 1
  • (Upper image) Large ulceration of the lower labial mucosa of a patient receiving deforolimus (AP23573) is shown. The borders were irregular. Although the ulcer was not penetrating, it was extremely painful. The clinical appearance was identical to that of major aphthous stomatitis.
Mucite buccale 2
Mucite buccale 3
  • Oral candidiasis, 51-year-old female, after the 18th fraction of radiotherapy in the OPC group. Whitish pseudomembranes and drops (arrows) are observed on the hard palate, which is devoid of mucositis (A). (A). Mucositis grade 2 to 3, 57-year-old male, after the 25th fraction of radiotherapy in the non-OPC group. Whitish pseudomembranes and drops (arrows) are observed on the hard palate, which is devoid of mucositis (A). (B). (OPC: oropharyngeal candidiasis)

Platform of galenic solutions

Answers to a proven medical need to reduce the side adverse effects of chemo and radiotherapy (inflammation, mucositis, oral candidiasis) using scientifically validated natural phytotherapeutic and probiotic products, that have been scientifically validated.

Mouthwash

Mouth Spray

Mouth gel

stick blanc

Stick

N

Phytotherapeutic galenic platform

  • Mouthwash / Mouth spray / Mouth gel
  • Developed galenic pre-formulas
  • Organic plants grown in Switzerland, in particular the willowherb, a cultivar developed over 3 years, rich in flavonoids and oenotheins A and B, resistant and fast growing
  • Clinical safety and skin compatibility tested
  • Microbiological stability tested (28 days)
  • Preliminary proof of efficacy in oncology
N

Probiotic specific to the oral sphere

  • Existing base formula
  • Adaptable formula for worldwide exclusivity
  • Available clinical studies
A

Cultures of organic Epilobium parviflorum in Valais

The small-flowered willowherb (Epilobium parviflorum), from the Onagraceae family, is used in traditional medicine for its antioxidant, antimicrobial and anti-inflammatory properties. Over the course of several years, we have selected a cultivar and developed an extraction process that allows us to obtain an extract particularly rich in Oenothein B, an active ingredient at the origin of the IBEX Tx innovation because of its anti-adhesion activity against C. albicans. The small-flowered willowherb used in IBEX Tx is grown in the Swiss Alps according to the principles of organic farming.

Cultures of organic Epilobium parviflorum in Valais

The small-flowered willowherb (Epilobium parviflorum), from the Onagraceae family, is used in traditional medicine for its antioxidant, antimicrobial and anti-inflammatory properties. Over the course of several years, we have selected a cultivar and developed an extraction process that allows us to obtain an extract particularly rich in Oenothein B, an active ingredient at the origin of the IBEX Tx innovation because of its anti-adhesion activity against C. albicans. The small-flowered willowherb used in IBEX Tx is grown in the Swiss Alps according to the principles of organic farming.

Cultures of organic Epilobium parviflorum in Valais
Nos cultures dEpilobium parviflorum BIO en Valais 3
Nos cultures dEpilobium parviflorum BIO en Valais 2

About

  • IBEX Therapeutics, a Swiss company specialised in therapies based on biological products derived from plant extracts.
  • Founded in 2021 by 4 co-founders with solid experience in the pharmaceutical industry.
  • Subsidiary company of PHARMALP SA used to create an opportunity to leverage a patent by investing in the development of a pharmaceutical product.
  • Mission: To bring the first product to market within 3 years with a solid proof of concept.

The company

Z

Subsidiary company of PHARMALP SA used to create an opportunity to leverage a patent by investing in the development of a pharmaceutical product

Z

EU and US patent "Epilobium-anti-Candida" owned by PHARMALP SA

Z

Patent available, filed in 2014 (EU) and 2015 (US), protection until 2034 and 2035 respectively

Z

PHARMALP SA patent license in the field of oral health in peri-oncology.

Z

Galenic pre-formulas developed with phytomedicines or food supplements status

Z

Proven technological capacity for both the production of the active ingredient and the manufacture of the finished product. The technology is resting on robust know-how in culture and extraction

Z

Objective: Market the natural products intended to reduce the side effects of cancer chemo and radiotherapy in the oral sphere and then expand towards other areas of application

A

The company

Z

Subsidiary company of PHARMALP SA used to create an opportunity to leverage a patent by investing in the development of a pharmaceutical product

Z

EU and US patent "Epilobium-anti-Candida" owned by PHARMALP SA

Z

Patent available, filed in 2014 (EU) and 2015 (US), protection until 2034 and 2035 respectively

Z

PHARMALP SA patent license in the field of oral health in peri-oncology.

Z

Galenic pre-formulas developed with phytomedicines or food supplements status

Z

Proven technological capacity for both the production of the active ingredient and the manufacture of the finished product. The technology is resting on robust know-how in culture and extraction

Z

Objective: Market the natural products intended to reduce the side effects of cancer chemo and radiotherapy in the oral sphere and then expand towards other areas of application

About

  • IBEX Therapeutics, a Swiss company specialised in therapies based on biological products derived from plant extracts.
  • Founded in 2021 by 4 co-founders with solid experience in the pharmaceutical industry.
  • Subsidiary company of PHARMALP SA used to create an opportunity to leverage a patent by investing in the development of a pharmaceutical product.
  • Mission: To bring the first product to market within 3 years with a solid proof of concept.
  • Values: 2 to 3 values to be discussed together.
Logo Ibex Therapeutics

The Ibex Therapeutics team

Board of Directors

Multidisciplinary team with expertise in the key areas of development (technical, medical, regulatory and commercial).

The Ibex Therapeutics team

Board of Directors

Multidisciplinary team with expertise in the key areas of development (technical, medical, regulatory and commercial).

Equipe

Board of Directors

(from left to right): Philippe Meuwly – Alain Rinaldi – Pierre Morgon – Alain Merkli

The Ibex Therapeutics team

Board of Directors

Multidisciplinary team with expertise in the key areas of development (technical, medical, regulatory and commercial).

Equipe

Board of Directors

(from left to right): Philippe Meuwly – Alain Rinaldi – Pierre Morgon – Alain Merkli

Partners

Phytotherapeutic range

Production finished product

Probiotic range

Pharmaceutical development

Partners

Phytotherapeutic range

Production finished product

Probiotic range

Pharmaceutical development

IBEX logo compact grey green

Phone

+41 (27) 346 50 50

E-Mail

contact@ibextx.ch

Address

PhytoArk,
Route des Eterpys 22
CH-1964 Conthey
Switzerland

Contact us

3 + 11 =

IBEX logo compact grey green

Phone

+41 (27) 346 50 50

E-Mail

contact@ibextx.ch

Address

PhytoArk
Route des Eterpys 22
CH-1964 Conthey
Switzerland

Contact us

11 + 11 =

© 2022 Ibex Therapeutics

Terms of use

Website designed by capsun-web.ch

© 2022 Ibex Therapeutics

Website designed by capsun-web.ch